For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

More >>
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>
Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.

More >>

Cell Therapy’s Promise for Canadians Must Include Access

An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.

More >>

Planned trials


A Prospective Feasibility Sub-Study of BL13 - e-PRISM


International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III


Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma


Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>


Fulvestrant and Ipatasertib for Advanced/Metastatic HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)


Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>


Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer


Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated


MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC

More >>


Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease

More >>


Circulating tumOr DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

More >>


COV-IMMUNO - Immunization with IMM-101 vs Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

More >>


NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

More >>


Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients

More >>


Impact of COVID-19 Pandemic on Cancer Patients During Treatment and Survivors

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>


A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226

Lung Cancer 143: 1 - 11, 2020
Juergens RA;Hao D;Ellis PM;Tu D;Mates M;Kollmannsberger C;Bradbury PA;Tehfe M;Wheatley-Price P;Robinson A;Bebb G;Laskin J;Goffin J;Hilton J;Tomiak A;Hotte S;Goss GD;Brown-Walker P;Sun X;Tsao MS;Cabanero M;Gauthier I;Song X;Dennis PA;Seymour LK;Smoragiewicz M;Laurie SA;

More >>

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia (ONLINE)

Leuk Lymphoma : 1 - 7, 2020
Assouline S;Amrein L;Aloyz R;Banerji V;Caplan S;Owen C;Hasegawa W;Robinson S;Shivakumar S;Prica A;Peters A;Hagerman L;Rodriguez L;Skamene T;Panasci L;Chen BE;Hay AE;

More >>

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies (ONLINE)

Invest New Drugs , 2020
Nehra J;Bradbury PA;Ellis PM;Laskin J;Kollmannsberger C;Hao D;Juergens RA;Goss G;Wheatley-Price P;Hotte SJ;Gelmon K;Tinker AV;Brown-Walker P;Gauthier I;Tu D;Song X;Khan A;Seymour L;Smoragiewicz M;

More >>

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3)

International Journal of Radiation Oncology*Biology*Physics 106: 255 - 260, 2020
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;

More >>